Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01388543 · ClinicalTrials.gov registry record · Phase 4
Genetics and HIV-1 Protease Inhibitors
A Phase 4 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
NCT01388543 is a Phase 4 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 31 participants.
The verdict
NCT01388543, a Phase 4 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
Study Summary
This study evaluated the blood levels of atazanavir according to a genetic makeup for CYP3A5 (cytochrome P450 3A5, an enzyme that metabolizes atazanavir). The hypothesis was that people with a slow-metabolizing genotype would have higher blood levels of atazanavir compared to people with the normal metabolizing genotype.
Interventions
- DRUG Atazanavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2006-09 |
| Est. Completion | 2008-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01388543
The ClinicalTrials.gov registry entry for NCT01388543 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atazanavir is the first listed.
NCT01388543 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01388543 about?
NCT01388543 is a clinical study titled "Genetics and HIV-1 Protease Inhibitors". This study evaluated the blood levels of atazanavir according to a genetic makeup for CYP3A5 (cytochrome P450 3A5, an enzyme that metabolizes atazanavir). The hypothesis was that people with a slow-metabolizing genotype would have higher blood levels of atazanavir compared to people with the normal ...
What is the current status of trial NCT01388543?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2006-09. Estimated completion is 2008-06.
What interventions are being tested in trial NCT01388543?
The interventions under investigation include: Atazanavir (DRUG).
Who is sponsoring clinical trial NCT01388543?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.